Evidence map›Paper›PMID 41896882›Full record

ReviewOrphanet journal of rare diseases2026

Burden and severity of inherited monoamine neurotransmitter rare genetic disorders in India.

Runa Hamid, Vykuntaraju K Gowda, Lloyd Tauro, Rakesh Mishra

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Runa HamidTata Institute for Genetics and Society, Bengaluru, Karnataka, India. runa.hamid@tigs.res.in.ORCID http://orcid.org/0000-0001-9109-0467
Vykuntaraju K GowdaDepartment of Pediatric Neurology, Indira Gandhi Institute of Child Health, Bengaluru, Karnataka, India.
Lloyd TauroTata Institute for Genetics and Society, Bengaluru, Karnataka, India.
Rakesh MishraTata Institute for Genetics and Society, Bengaluru, Karnataka, India.

Funding

Tata Trusts Tata Trusts
6 · The paper itself

Abstract

Monoamine neurotransmitter metabolic disorders (mNMDs) are a diverse group of rare genetic conditions caused by disruptions in the metabolism of catecholamines (dopamine, epinephrine, and norepinephrine) and serotonin. These disorders predominantly affect children, often manifesting as neurodevelopmental and mental health challenges. Despite their clinical significance, there is a conspicuous lack of comprehensive reviews focused on the Indian population. The prevalence and distribution of mNMDs within India remain largely unexplored, underlining an urgent need for systematic data collection and analysis. This review aims to address this knowledge gap by compiling individual case reports of mNMDs documented in India, identifying genetic factors contributing to these conditions, and describing their manifestations. It provides an overview of diagnosed cases of mNMDs from various hospitals across the country, emphasizing the current limitations of diagnostic tools and the need for specialized testing. By illuminating mNMDs occurrence and clinical characteristics in India, this review seeks to encourage greater awareness about these disorders in India and the need to develop effective diagnostic and therapeutic strategies.

Indexed as

Biogenic MonoaminesNeurotransmitter AgentsRare DiseasesAromatic-L-Amino-Acid DecarboxylasesHumansIndiaAromatic-L-Amino-Acid DecarboxylasesBiogenic MonoaminesNeurotransmitter AgentsAromatic L-amino acid decarboxylaseDopamineGTPCH1HyperphenylalaninemiaMonoamine neurotransmitter disordersOculogyric crisisRare genetic disordersSerotoninTetrahydrobiopterinTyrosine hydroxylase

Identifiers

PMID41896882
PMCPMC13147586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.